NASDAQ
Prothena Corporation plc - Ordinary Shares (PRTA)
♥ 606 Thanks from members
Prothena Corporation plc (PRTA) presents a high-asymmetry biotech profile, balancing heavy cash burn, thin Q2 collaboration revenues, and a low Piotroski score against massive DCF-modeled upside, high institutional ownership, and active pipeline developments like the PRX019 phase I study with Bristol Myers Squibb.